Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Issues Safety Warning on Use of Afinitor in HBV Carriers
March 30, 2012
- Office of Medical Innovation Begins Discussions on “Five-year Strategy for Medical Innovation”, Compiles Interim Report by Mid-April
March 29, 2012
- “MHLW Ideal” Placement for Drug Discovery Support Organization: Medical Innovation Office Counselor Hachiyama
March 28, 2012
- Handling of Adverse Reaction Data an Issue in Access System Adaptation: MHLW Deputy Director Miyata
March 28, 2012
- Eight Products/Indications Including Xalkori to Receive Formal Approval by End of Month
March 28, 2012
- Use of Medicoeconomic Assessment in Drug Pricing “Unrealistic”: DG for Policy Planning and Evaluation Katori
March 28, 2012
- MHLW Study Group Decides on Next 5-Year Plan for Activation of Clinical Research
March 27, 2012
- Council for Improvement of the Distribution of Ethical Drugs Agrees to Establish Working Team, Focus on Spreading “Mutual Understanding”
March 27, 2012
- “No Serious ADR” Found in MHLW’s Fixed-Point Observation for Byetta
March 27, 2012
- Council Approves 80 Development Requests from 2nd Round
March 27, 2012
- PMDA to Improve Review, Safety Standards to Become World-Class Regulatory Authority: Chief Executive Kondo
March 26, 2012
- Notification Calls for Revision of Package Inserts for Diabetes, MS Treatments
March 23, 2012
- Kawasaki’s Tonomachi District to Invite NIHS, Set to Become International Basis for R&D
March 23, 2012
- Eliminating Drug Lag Will Require Measures to Reduce “Application Lag”: Mr Akagawa of PFSB
March 22, 2012
- Council Meeting Considers Working Team to Explore Directions for Drug Distribution Improvement
March 21, 2012
- Pharmaceutical Industry Should be Fostered as “Core Industry Taxed Not Punished”: Mr Sengoku of DPJ
March 21, 2012
- CSIMC to Accelerate Discussions on Long-Listed Drugs, Cost-Benefit Assessments: Dr Suzuki of HIB
March 21, 2012
- Health Insurance Claims Services Releases 37 Additional Cases Based on “1980 Notice”
March 19, 2012
- Generics Not Listed in All Specifications to Be Delisted from April 1 with Some Exceptions
March 19, 2012
- MHLW Submits Application for Membership in PIC/S on March 9
March 19, 2012
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…